NO20004881L - Pyrrolo[1,2-a]pyrazin sPLA2 inhibitor - Google Patents

Pyrrolo[1,2-a]pyrazin sPLA2 inhibitor

Info

Publication number
NO20004881L
NO20004881L NO20004881A NO20004881A NO20004881L NO 20004881 L NO20004881 L NO 20004881L NO 20004881 A NO20004881 A NO 20004881A NO 20004881 A NO20004881 A NO 20004881A NO 20004881 L NO20004881 L NO 20004881L
Authority
NO
Norway
Prior art keywords
pyrrolo
pyrazine
atoms
similar
group
Prior art date
Application number
NO20004881A
Other languages
English (en)
Other versions
NO20004881D0 (no
Inventor
Mitsuaki Ohtani
Masahiro Fuji
Tetsuo Okada
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO20004881D0 publication Critical patent/NO20004881D0/no
Publication of NO20004881L publication Critical patent/NO20004881L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Formel (I), hvori Rer -(L)-Rhvorier en toverdig bindingsgruppe med 1 til 18 atomer eller lignende, oger en karbocyklisk ring substituert med minst en ikke-interfererende substituent eller lignende, Rer Cl til C3 alkyl, C3 til C4 cykloalkyl eller en lignende gruppe, Rer -(L2) -. (sur gruppe), Rog Rhydrogenatomer, ikke-interfererende substituenter, karbocykliske grupper eller lignende, "RA er. -C(=)-(=)-eller lignende, og X er uavhengig oksygen-atom eller svovelatom, prodrugs derav, deres farmasøytisk akseptable salter, eller deres solvater og et preparat for inhibering av sPLAinneholdende disse som effektive bestand-deler .
NO20004881A 1998-03-31 2000-09-28 Pyrrolo[1,2-a]pyrazin sPLA2 inhibitor NO20004881L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8599798 1998-03-31
JP24473598 1998-08-31
PCT/JP1999/001670 WO1999051605A1 (en) 1998-03-31 1999-03-31 PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR

Publications (2)

Publication Number Publication Date
NO20004881D0 NO20004881D0 (no) 2000-09-28
NO20004881L true NO20004881L (no) 2000-11-28

Family

ID=26427020

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004881A NO20004881L (no) 1998-03-31 2000-09-28 Pyrrolo[1,2-a]pyrazin sPLA2 inhibitor

Country Status (11)

Country Link
US (1) US6407104B1 (no)
EP (1) EP1066290A1 (no)
JP (1) JP4412521B2 (no)
KR (1) KR20010042307A (no)
CN (1) CN1303384A (no)
AU (1) AU3054399A (no)
BR (1) BR9909345A (no)
CA (1) CA2326522A1 (no)
HU (1) HUP0102981A3 (no)
NO (1) NO20004881L (no)
WO (1) WO1999051605A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6004799A (en) 1998-10-14 2000-05-01 Shionogi & Co., Ltd. Remedies or preventives for ischemic reflow failure
WO2001005789A1 (fr) 1999-07-19 2001-01-25 Shionogi & Co., Ltd. Composes tricycliques a action inhibitrice a l'encontre de spla¿2?
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
AU1304801A (en) 1999-11-15 2001-05-30 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an SPLA2- inhibiting effect
WO2002000256A1 (en) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cirrhosis
US7026318B2 (en) 2000-06-29 2006-04-11 Shionogi & Co., Ltd. Compounds exhibiting X-type sPLA2 inhibiting effect
AUPQ876400A0 (en) * 2000-07-14 2000-08-03 University Of Queensland, The Compositions and method of using them
AU2001280461A1 (en) * 2000-08-04 2002-02-18 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
TWI314457B (no) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
DE10155727A1 (de) * 2001-11-13 2003-05-28 Morphochem Ag Serin Protease Inhibitoren
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
WO2007019417A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
CN105622616A (zh) * 2016-02-25 2016-06-01 上海雅本化学有限公司 一种4-氯吡咯并嘧啶的制备方法
WO2023042716A1 (ja) * 2021-09-17 2023-03-23 三井化学株式会社 （メタ）アクリルアミド化合物の製造方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
CO4370099A1 (es) 1994-04-01 1996-10-07 Lilly Co Eli 1H-INDOL-3-GLIOXILAMIDAS INHIBIDORAS DE sPLA2
US6214876B1 (en) * 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
ES2208685T3 (es) * 1994-07-21 2004-06-16 Eli Lilly And Company Inhibidores de indolizina spla2.
KR19990072111A (ko) 1995-12-13 1999-09-27 피터 지. 스트링거 Spla2 억제제인 나프틸 글리옥스아미드
KR19990072110A (ko) 1995-12-13 1999-09-27 피터 지. 스트링거 Spla2 억제제인 나프틸 아세트아미드
BR9713261A (pt) 1996-10-30 2000-03-28 Lilly Co Eli Tricìclicos substituìdos
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
TW455581B (en) 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides

Also Published As

Publication number Publication date
US6407104B1 (en) 2002-06-18
CA2326522A1 (en) 1999-10-14
EP1066290A1 (en) 2001-01-10
JP4412521B2 (ja) 2010-02-10
HUP0102981A3 (en) 2002-10-28
BR9909345A (pt) 2000-12-12
JP2002530268A (ja) 2002-09-17
CN1303384A (zh) 2001-07-11
KR20010042307A (ko) 2001-05-25
HUP0102981A2 (hu) 2002-01-28
NO20004881D0 (no) 2000-09-28
AU3054399A (en) 1999-10-25
WO1999051605A1 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
NO20004881L (no) Pyrrolo[1,2-a]pyrazin sPLA2 inhibitor
BR9911048A (pt) Inibidor de spla2 de pirrolo[1,2-b]piridazina
NO20012570L (no) Substituerte benzimidazoler og deres anvendelse som PARP- inhibitorer
NZ507564A (en) 4-substituted carbazole or tetrahydrocarbazole derivatives
CA2205757A1 (en) Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
DK1106612T3 (da) Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase
MX9701893A (es) Nuevos inhibidores de la prostaglandinsintasa.
DK1178967T3 (da) Quinolinderivater som inhibitorer af MEK-enzymer
AU5702996A (en) Oxygen-containing heterocyclic compounds
EP0989129A4 (en) PYRAZOLOPYRIDYLPYRIDAZINONE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF
CO5011045A1 (es) Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos
ATE202567T1 (de) Phosphorsäurediester-derivate
DK0628550T3 (da) Pyridazin som interleukin-1 beta-omdannede enzyminhibitorer
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
HRP20000585B1 (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
TW352383B (en) Hydroximic acid derivatives, processes for their preparation, and compositions comprising them
TW200624541A (en) Flameproof rubber-reinforced styrenic resin composition
YU19099A (sh) Supstituisani tricikli
DK0746545T3 (da) Nipecotinsyrederivater som antithrombotiske forbindelser
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
NO934227L (no) Pyrrolderivater, fremgangsmåte for deres fremstilling og terapeutiske anvendelse
TW262467B (no)
EP0133038A3 (en) Octahydroindolizinepropanoic acid derivatives as enzyme inhibitors
MY133207A (en) Substituted benzolactam compaunds
BG102429A (en) Derivatives of 5-naphthalen-1-yl-1,3-dioxan, their preparation and usage as therapeutical means